Friday, April 15, 2016 9:06:13 PM
REAL-WORLD SAFETY AND EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/R ±
DASABUVIR ± RIBAVIRIN IN THE GERMAN HEPATITIS C REGISTRY (clear version)
http://www.natap.org/2016/EASL/EASL_19.htm
Please visit natap for many other EASL programs
"only 6 of 558 (1.1%) patients experienced virologic relapse"
=====================
See also
The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort
http://www.natap.org/2016/EASL/EASL_16.htm
=========================
Analysis of the Real-World Effectiveness of Direct Acting Antiviral Treatments for Hepatitis C in a Large Population.
ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF DIRECT ACTING ANTIVIRAL TREATMENTS FOR HEPATITIS C IN A LARGE POPULATION
"Introduction: Documentation of the effectiveness of direct acting antiviral treatments for hepatitis C in a large real-world population is limited. We evaluated the effectiveness of simeprevir/sofosbuvir, ledipasvir/sofosbuvir, and ombitasvir/paritaprevir/ritonavir/dasabuvir for the treatment of hepatitis C patients within the United States Veterans Health Administration.
Material and Methods: Study patients were selected if they used one of the study treatments, completed treatment prior to September 1, 2015, and had a viral load test occurring at least 12 weeks after end-of-treatment. Treatment effectiveness was defined as having achieved a sustained virologic response at 12 weeks post-treatment. Effectiveness rates were estimated across all three treatments, and multivariate logistic analysis was employed to explore the impact of treatment type, controlling for patient and disease characteristics.
Results: A total of 9,604 patients met the study inclusion criteria. The unadjusted rates of effectiveness were 87.3% for simeprevir/sofosbuvir [N=3,068], 93.2% for ledipasvir/sofosbuvir [N=5,524], and 93.4% for ombitasvir/paritaprevir/ritonavir/dasabuvir [N=1,012]. Simeprevir/sofosbuvir yielded lower effectiveness rates than the other two study treatments (O.R.= 0.64, [0.49-0.85]). Other results from the logistic regression analysis found that patients with cirrhosis, decompensated cirrhosis or hepatocellular carcinoma at the start of treatment were less likely to achieve sustained virologic response. Black and male patients were less likely to achieve sustained virologic response, while co-infection with HIV, hepatitis B, diabetes and obesity had no impact on treatment effectiveness. There was some limited evidence that patients younger than 60 years of age were less likely to respond.
Conclusion: Overall rates of effectiveness exceeded 87% across all three direct-acting antiviral treatments. Rates of treatment effectiveness for ledipasvir/sofosbuvir and ombitasvir/paritaprevir/ritonavir/dasabuvir were greater than 81% for all subgroups.
=====================
EASL saturday program
"DASABUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: REAL LIFE INTERIM ANALYSIS OF AN ITALIAN MULTICENTRE COMPASSIONATE USE PROGRAM"
Recent ENTA News
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference • Business Wire • 03/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:31:52 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 06:11:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:23:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:21:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:18:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:15:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:12:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:09:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:00:28 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:26:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:24:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:05:12 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 02/07/2024 09:01:00 PM
- Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/06/2024 12:00:00 PM
- Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023 • Business Wire • 01/31/2024 12:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM